Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease

BACKGROUND: Vedolizumab, an α4β7 integrin antagonist, is an effective therapy for Crohn’s disease (CD). Biomarkers are needed to guide therapy and predict outcomes. This study evaluated biomarker concentrations and outcomes in patients with CD undergoing vedolizumab treatment. METHODS: Sera at weeks...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Therap Adv Gastroenterol
Prif Awduron: Holmer, Ariela K., Battat, Robert, Dulai, Parambir S., Vande Casteele, Niels, Nguyen, Nghia, Jain, Anjali, Miralles, Ara, Neill, Jennifer, Le, Helen, Singh, Siddharth, Rivera-Nieves, Jesus, Sandborn, William J., Boland, Brigid S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: SAGE Publications 2020
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7675888/
https://ncbi.nlm.nih.gov/pubmed/33240396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284820971214
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg